Equivalent of Form PTO/SB/08A (07-06) Approved for use through 09/30/2006. OMB 0551-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

		Under the	Paperwork Reduction Act of 1995,	no persons are required to respond to a collec-	tion of information unless it contains a valid OMB control number.
Substitute 1	Substitute for form 1449A/PTO			Complete	if Known
INFOR	INFORMATION DISCLOSURE		Application Number	10/567,788 (Natl. Phase of PCT/EP2004/008688)	
			Intl. Filing Date	August 2, 2004 2 EA .	
	STATEMENT BY APPLICANT			First Named Inventor	FISCHER, Reincia 6 2
	(Use as	many she	ets as necessary)	Art Unit	1616
				Examiner Name	To Be Assigned
Sheet	1	of	3	Attorney Docket Number	2400.0210000/JMC/CMB*AFKO

			U.S. PATENT DO	CUMENTS	
Examiner Initials	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages
/Y.G./	NO.	Number-Kind Code <sup>2 (If Kuma)</sup>		Applicant of Cited Document	or Relevant Figures Appear
, 1.0,	USI	3,542,809	11/24/1970	Nakanishi, Susumu	
	US2	3,989,503	11/02/1976	Pallos et al.	
	US3	4,021,224	05/03/1977	Pallos et al.	
1	US4	4,623,727	11/18/1986	Hubele	
T	US5	4,639,266	01/27/1987	Heubach et al.	
	US6	4,881,966	11/21/1989	Nyffeler et al.	
$\Psi -$	US7	4,891,057	01/02/1990	Sohn et al.	
YYC./	US8	4,902,340	02/20/1990	Hubele	

			REIGN PATENT DO			
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where	
		Country Code* Number* Kind Code* (if known)			Relevant Passages or Relevant Figures Appear	T⁴
/Y.C./	FPI	DE 1 945 703	07/02/1970	Chas. Pfizer & Co. Inc.		
I	FP2	DE 2 218 097	11/02/1972	Stauffer Chemical Co.		
	FP3	DE 2 350 547	04/25/1974	Stauffer Chemical Co.		
	FP4	EP 0 086 750 A2	08/24/1983	Ciba-Geigy AG		
	FP5	EP 0 094 349 A2	11/16/1983	Ciba-Geigy AG		
	FP6	EP 0 174 562 A2	03/19/1986	Hoechst Aktiengesellschaft		
	FP7	EP 0 191 736 A2	08/20/1986	Ciba-Geigy AG		
	FP8	EP 0 269 806 A1	06/08/1988	Hoechst Aktiengesellschaft		
	FP9	EP 0 333 131 A1	09/20/1989	Hoechst Aktiengesellschaft		
	FP10	EP 0 346 620 A1	12/20/1989	Hoechst Aktiengesellschaft		Abs
	FP11	WO 91/07874 A1	06/13/1991	Hoechst Aktiengesellschaft		Abs
	FP12	WO 91/08202 A1	06/13/1991	Hoechst Aktiengesellschaft		Abs
	FP13	EP 0 492 366 A2	07/01/1992	Hoechst Aktiengesellschaft		
	FP14	WO 92/16510 A1	10/01/1992	Ciba-Geigy AG		
	FP15	EP 0 508 126 A1	10/14/1992	Bayer AG		
	FP16	EP 0 528 156 A1	02/24/1993	Bayer AG		
	FP17	EP 0 582 198 A2	02/09/1994	Hoechst Aktiengesellschaft		
	FP18	EP 0 613 618 A1	09/07/1994	American Cyanamid Co.		
W	FP19	WO 94/29268 A1	12/22/1994	Bayer Aktiengesellschaft		Abs
/Y.C./	FP20	WO 95/07897 A1	03/23/1995	Hoechst Schering AgrEvo GmbH		Abs

Examiner Signature	Yong Chu	/				Date Considered	01/2	4/20	109			
			 	 	 		 			 		_

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPIOP related Documents at www.usplo.gov or MPEP 9010 44. 'Enter Office that issued the document, by the whether code (DS blands of S1,3'.'). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the petent document. 'Kind of document by the appropriate's sprincis as indicated on the document of the WPO Standard S1,3'. Applicant is to jude note what where it is not to the petent document by the appropriate's sprincis as indicated on the document upon the WPO Standard S1,16' it possible.' Applicant is to jude note what where it is not to the petent document by the appropriate's sprincis as indicated on the document by the appropriate sprincis as indicated on the document of the series of the petent document of the petent document of the petent of the petent document of the petent d English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Certificatingly is governed by 38 U.S.C. 122 and 37 CFR 1.14f. This collection is expected by the USPTO to process) an application. Certificatingly is governed by 38 U.S.C. 122 and 37 CFR 1.14f. This collection is expected by the USPTO to process) an application. Certificatingly is governed by 38 U.S.C. 122 and 37 CFR 1.14f. This collection is expected by the USPTO to complete, including paths and process. The USPTO the U

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Equivalent of Form PTO/SB/08A (07-05)
Approved for use through 05/03/000 00/08 065-10031
U.S. Patent and Tratemark Office, U.S. CEPARTMENT OF COMMERCE

		Under the	Paperwork Reduction Act of 1	995, no persons are required to respond to a colle	ection of information unless it contains a valid OMB control number.
Substitute	Substitute for form 1449A/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Complet	e if Known
IN EQ.				Application Number	10/567,788 (Natl. Phase of PCT/EP2004/008638)
				Intl. Filing Date	August 2, 2004
				First Named Inventor	FISCHER, Reiner
	(Use as	many she	ets as necessary)	Art Unit	1616
				Examiner Name	To Be Assigned
Sheet	2	of	3	Attorney Docket Number	2400.0210000/JMC/CMB

	U.S. PATENT DOCUMENTS							
Examiner Initials	Cite	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines,			
	No.	Number-Kind Code <sup>2 (IFKaowa)</sup>	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear			
-/Y.C./	US9	5,262,383	11/16/1993	Fischer et al.				
	US10	5,332,720	07/26/1994	Kruger et al.				
	USII	5,380,852	01/10/1995	Schutze et al.				
W	US12	5,401,700	03/28/1995	Sohn et al.				
/W.C./	US13	5,739,079	04/14/1998	Holdgrun et al.				

FOREIGN PATENT DOCUMENTS

			FOREIGN PATENT DO			
Examiner Initials*	Cite No.'	Foreign Patent Document Country Code* Number* Kind Code* (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	FP21	WO 96/21652 A1	07/18/1996	Ciba-Geigy AG		
1	FP22	WO 96/35664 A1	11/14/1996	Bayer Aktiengesellschaft		Abs
	FP23	WO 96/36229 A1	11/21/1996	E.I. Du Pont De Nemours and Company		
	FP24	WO 96/36615 A1	11/21/1996	E.I. Du Pont De Nemours and Company		
	FP25	WO 96/36616 A1	11/21/1996	E.I. Du Pont De Nemours and Company		
	FP26	WO 96/36633 A1	11/21/1996	E.I. Du Pont De Nemours and Company		
	FP27	WO 96/37494 A1	11/28/1996	Zeneca Limited		
	FP28	WO 97/01535 A1	01/16/1997	Bayer Aktiengesellschaft		Abs
	FP29	WO 97/02243 A1	01/23/1997	Bayer Aktiengesellschaft		Abs
	FP30	WO 97/36868 A1	10/09/1997	Bayer Aktiengesellschaft		Abs
	FP31	DE 196 21 522 A1	12/04/1997	Hoechst Schering AgrEvo GmbH		
	FP32	WO 98/05638 A2	02/12/1998	Bayer Aktiengesellschaft		Abs
	FP33	WO 98/25923 A1	06/18/1998	Zeneca Limited		
	FP34	WO 99/43649 A1	09/02/1999	Bayer Aktiengesellschaft		Abs
<b>X</b> .	FP35	WO 99/47525 A1	09/23/1999	Novartis AG; Novartis- Erfindungen Verwaltungsgesellschaft mbh		

Signature Considered 01724/2009	Examiner Signature	/Yong Chu/	Date Considere	ed 01/24/2009	
---------------------------------	-----------------------	------------	-------------------	---------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this torm with next communication to applicant. Applicant's unique citation designation number of polynoming. See Ninds Codes For Japanese patient of the present comments, the indication of the year of the reign of the Emperor must precede the seafful number of the patient document. Nind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is statuted.

English lenguage Translation is attached.

This collection of information is required by 37 CFR 197 and 198. The information is required to obtain or retain a benefit by the public which is to file (and byth of the public which is to file (an

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Equivalent of Form PTO/SB/08A (07-06)

2400.0210000/JMC/CMB

Approved for use through 09/00/2006, OMB 0651-0031

U.S. Platent and Trainark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless to contains a valid Ottor foundation. Substitute for form 1449A/PTO Complete if Known 10/567,788 (Natl. Phase of Application Number PCT/EP2004/008638) INFORMATION DISCLOSURE Intl. Filing Date August 2, 2004 STATEMENT BY APPLICANT First Named Inventor FISCHER, Reiner (Use as many sheets as necessary) Art Unit 1616 Examiner Name To Be Assigned

Attorney Docket Number

Examiner Cite		Document Number	U.S. PATENT Do Publication Date	Name of Patentee or	Pages, Columns, Lines,
Initials	No.1	Number-Kind Code <sup>2 (If Kerven)</sup>	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear
/Y.C./	US14	6,235,680 B1	05/22/2001	Ziemer et al.	
/Y.C./	US15	6,251,827 B1	06/26/2001	Ziemer et al.	

Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns,	
lnitials*	No.	Country Code <sup>5</sup> Number <sup>6</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
/Y.C./	FP36	WO 99/48869 A1	09/30/1999	Bayer Aktiengesellschaft		ISR
	FP37	WO 99/55673 A1	11/04/1999	Bayer Aktiengesellschaft		Abs
	FP38	WO 99/66795 A1	12/29/1999	Hoechst Schering AgrEvo GmbH		Abs
	FP39	WO 01/17351 A1	03/15/2001	Syngenta Participations AG		
	FP40	WO 01/17352 A1	03/15/2001	Syngenta Participations AG		Abs
	FP41	WO 01/17353 A1	03/15/2001	Syngenta Participations AG		
	FP42	WO 01/17972 A2	03/15/2001	Syngenta Participations AG		Abs
	FP43	WO 01/17973 A2	03/15/2001	Syngenta Participations AG		ISR
	FP44	WO 03/028446 A2	04/10/2003	Evotecoai AG		
	FP45	WO 03/045957 A1	06/05/2003	Bayer Cropscience Aktiengesellschaft		ISR
N.C./	FP46	WO 03/062244 A1	07/31/2003	Syngenta Participations AG		

590125v1

Sheet

3 of

Examiner Signature	/Yong Chu/	Date Considered	01/24/2009
-----------------------	------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include copy of this form with next commendation is applicant. Applicants unique citation designation number (opinions). See Kinds Codes For Japanese patient documents, the indication of the layer of the reign of the first procedule is setficial number of the producement. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attacked.

English language Translation is attached. 37 CFR 1.97 and 1.98. The internation is required to obtain or retain a benefit by the subtic which is to file (and This collection of information is required and only of the collection is eligible to label 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form andors suggestions for reducing this burner, should be set for Christian Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DN OTSEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Commissions for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (07-06) Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO	sbstitute for form 1449B/PTO		Complete if Known		
INFORMATION DIGG	LOCUEE	Application Number	10/567,788 (Natl Phase of PCT/EP2004/008638)		
INFORMATION DISC		Intl. Filing Date	August 2, 2004 FEB		
	STATEMENT BY APPLICANT		FISCHER, Reiner		
(Use as many sheets as necessary)		Art Unit	1616		
		Examiner Name	To Be Assigned		
Sheet 1 of	2	Attorney Docket Number	2400.0210000/JMC/CMB		

12 3

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
/Y.C./	NPL1	Askani, R., "Reaction of 1,3-cyclohexadiene with azodicarboxylic acid diethyl ester,"  Chem. Berichte 98:2551-2555, Verlag Chemie (1965)	Abs
	NPL2	STNEasy Database, Accession No. 1965:463065, English language abstract for Askani, R., "Reaction of 1,3-cyclohexadiene with azodicarboxylic acid diethyl ester," <i>Chem. Berichte</i> 98:2551-2555, Verlag Chemie (1965)	
	NPL3	Dannenberg, H. and Dannenberg-Von Dresler, D., "Synthesis of steranthrenes. III. 3,4- Aceperinaphtane and 6,7-aceperinaphtane," Ann. Chem. 535:1-15, Wienheim Verlag Chemie (1954)	Abs
	NPL4	STNEasy Database, Accession No. 1955:56638, English language abstract for Dannenberg, H. and Dannenberg-Von Dresler, D., "Synthesis of steranthrenes. III. 3,4-Aceperinaphthane and 6,7-aceperinaphtane," Ann. Chem. 585:1-15, Wienheim Verlag Chemie (1954)	
	NPL5	Diels, O., et al., "The endo-methylenepiperidazine resulting from cyclopentadiene and azo ester and its transformation diaminocyclopentane," Ann. Chem. 443:242-262, (1925)	Abs
	NPL6	STNEasy Database, Accession No. 1925:19216, English language abstract for Diels, O., et al., "The endo-methylenepiperidazine resulting from cyclopentadiene and azo ester and its transformation diaminocyclopentane," $Ann. Chem. 443:242-262, (1925)$	
	NPL7	Sonntag, N.O.V., "The Reactions of Aliphatic Acid Chlorides," Chem.Rev.52: 237-416, American Chemical Reviews (1953)	
	NPL8	Beilstein Database, Beilstein Registry No. 4957401, "ethyl 2-propylcarbazate," (entry date 1992)	
$\downarrow$	NPL9	Beilstein Database, Beilstein Registry No. 4968273, "ethyl 2,3-propylcarbazate," (entry date 1992)	
V.O.J	NPL10	International Search Report for International Patent Application No. PCT/EP2004/008638, mailed February 7, 2005, European Patent Office, The Netherlands	

Examiner Date /Yong Chu/ 01/24/2009 Signature Considered \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

<sup>&</sup>quot;EXAMINET: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicate." Applicant's unique citation designation number (optionals). \*Applicant's to place a check mark here if English language Translation is attached. \*Applicant's unique citation designation number (optionals). \*Applicant's to place a check mark here if English language Translation is attached. \*Applicant's unique citation designation number (optionals). \*Applicant to place a building of the building of the building of the building optionals of the building optionals of the building optional optionals of the building optionals of the building optionals of the building optionals optionals of the building optionals optio

PTO/SB/08B (07-06)

Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO		Con	Complete if Known	
		Application Number	10/567,788 (Natl. Phase of PCT/EP2004/008638)	
INFORMATION DISCL		Intl. Filing Date	August 2, 2004	
STATEMENT BY APPI		First Named Inventor	FISCHER, Reiner	
(Use as many sheets as n	ecessary)	Art Unit	1616	
		Examiner Name	To Be Assigned	
Sheet 2 of	2	Attorney Docket Number	2400.0210000/JMC/CMB	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>			
/Y.C./	NPL11	Esp@cenet Database, English language for EP 0 346 620 (listed on accompanying PTO/SB/08A as document FP10)				

590362v2

7-1 A-1

Examiner Signature	/Yong Chu/	Date Considered	01/24/2009	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

<sup>&</sup>quot;EXAMINET: Initial if reference considered, whether or not clation is in conformance with MPEP 809. Draw line through clation if not in conformance and not considered, include copy of this form with next communication to applicant is to place a check next here if English insupages Transistion Laterbad. Applicant's unique clation designation number (optional). Applicant is to place a check next here if English insupages Transistion Laterbad. Applicant's unique clation designation number (optional). Applicant's to place a check next here is a check next to explicate the conformation of the amount of time you require to complete this form andref raugestions for reducing this burden, should be sent her following the complete this form andref raugestions for reducing this burden, should be sent her following the complete this form andref raugestions for reducing this burden, should be sent her following the complete this form andref raugestions for reducing this burden, should be sent her following the complete this form andref raugestions for reducing this burden, should be sent her following the complete this form andref raugestions for reducing this burden, should be sent for the following the complete the form andref reducing this burden, should be sent for the following the complete the form and the